The ORYX team possesses many years of experience in developing biological substances through preclinical and clinical trials while simultaneously creating and protecting intellectual property rights.
Dr. Bernard Huber
Chief Executive Officer and Founder
Dr. Huber is a molecular biologist and patent attorney who has been involved in setting up several biotech companies. He has over 20 years experience in intellectual property rights protection, technology transfer and business management in the biotech sector. In 1996, Dr. Huber setup his own patent and law firm. Among others, since then, he has successfully represented the German Cancer Research Center (DKFZ) in patent/license matters regarding cervical cancer vaccines Gardasil® and Cervarix®.
Dr. Dr. Michael Dahm
Chief Medical Officer
Dr. Dahm is a medical doctor and molecular biologist with more than 10 years management experience in pharmaceutical companies. Prior to joining ORYX in 2009, he was Managing Director of HEXAL Biotech Forschungs GmbH and HEXAL Gentech Forschungs GmbH, where he was mainly responsible for the development of generic recombinant erythropoietin (EPO) and for the tumor cell enrichment system OncoQuick®.
Dr. Ottheinz Krebs
Chief Operating Officer
Dr. Krebs is a biochemist and virologist with more than 10 years experience in preclinical and clinical research. Prior to joining ORYX in 2008, he held management positions at Genelux Corp. and Metriopharm AG. His tasks at Genelux included the development of recombinant vaccinia viruses for tumor therapy.
Dr. Dr. Sven Rohmann
Chief Business Development Officer
Dr. Rohmann is a Life Science Manager with more than 20 years hands-on experience in preclinical and clinical research as well as marketing and business & corporate development. Currently, he is an independent Advisor for oncology and digital health and a board member of Helix Pharmaceuticals. Previously, he held management positions at Burrill & Company, Novartis Pharma AG and Nextech Venture AG. Before his career in venture capital, he spent 10 years with Merck Serono, where he led the establishment of Merck Oncology as its global head.